CareDxCDNA
CDNA
About: CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Employees: 650
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
67% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 5 (+2) [Q1 2025]
39% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 28
3% more funds holding
Funds holding: 210 [Q4 2024] → 217 (+7) [Q1 2025]
2.14% more ownership
Funds ownership: 98.9% [Q4 2024] → 101.04% (+2.14%) [Q1 2025]
12% less capital invested
Capital invested by funds: $1.14B [Q4 2024] → $995M (-$141M) [Q1 2025]
19% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 80
34% less call options, than puts
Call options by funds: $729K | Put options by funds: $1.11M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$25
34%
upside
Avg. target
$30
63%
upside
High target
$40
115%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Stephens & Co. Mason Carrico | 115%upside $40 | Overweight Reiterated | 5 May 2025 |
HC Wainwright & Co. Yi Chen | 34%upside $25 | Neutral Reiterated | 5 May 2025 |
Goldman Sachs Matthew Sykes | 40%upside $26 | Buy Maintained | 17 Apr 2025 |
Financial journalist opinion
Based on 4 articles about CDNA published over the past 30 days
Positive
Seeking Alpha
23 hours ago
CareDx: The Transplant Diagnostics Leader, But Challenges Will Increase On The Road Ahead
CareDx has a unique, comprehensive organ transplant diagnostics portfolio and maintains strong revenue growth, but faces intensifying competition and regulatory risks. Recent legal resolutions and operational improvements have strengthened the investment case, yet the company has never achieved operating profitability, raising concerns. Future growth depends on successful new product launches and expanding its ecosystem, but ongoing innovation is required to stay ahead of AI-driven competitors.
Neutral
Business Wire
1 week ago
CareDx Announces Repurchase of 5% of Outstanding Shares
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has completed the repurchase of $50 million of its common stock representing approximately 5% of outstanding shares. The share repurchase follows the completion of the company's seven.
Neutral
Business Wire
3 weeks ago
Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 30, 2020 and February 24, 2022, certain CareDx insiders caused the company to issue false and misleading public statements regarding its compliance with health.
Neutral
GlobeNewsWire
3 weeks ago
Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders
SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for potential breaches of fiduciary duties and violations of the federal securities laws.
Neutral
Business Wire
1 month ago
CareDx to Participate in Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences. Craig-Hallum 22nd Annual Institutional Investor Conference in Minneapolis, MN on Wednesday, May 28. Jefferies Global Health.
Neutral
Seeking Alpha
1 month ago
CareDx, Inc (CDNA) Q1 2025 Earnings Call Transcript
CareDx, Inc (NASDAQ:CDNA ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Caroline Corner - Investor Relations John Hanna - President & Chief Executive Officer Robert Woodward - Chief Scientific Officer Abhishek Jain - Chief Financial Officer Keith Kennedy - Chief Operating Officer Conference Call Participants Mason Carrico - Stephens Brandon Couillard - Wells Fargo Thomas DeBourcy - Nephron Research Operator Good day, everyone, and welcome to today's CareDx First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only-mode.
Positive
Zacks Investment Research
1 month ago
CareDx (CDNA) Tops Q1 Earnings Estimates
CareDx (CDNA) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.03 per share a year ago.
Neutral
Business Wire
1 month ago
CareDx Reports First Quarter 2025 Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the first quarter ended March 31, 2025. First Quarter Financial Highlights Reported first quarter revenue of $84.7 million, increased 18% year-over-year Testing services revenue of $61.9 million, increased 15% year-over-year, and testing services volume of approximately 47,100, increased 12% year-over-year GAAP net loss of $10.4 million, non-GAAP net income of $5.4 million, and positive adjusted.
Neutral
Business Wire
1 month ago
CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx, together with study collaborators, presented new scientific evidence on the use of AlloSure® Lung in clinical practice at the International Society for Heart and Lung Transplanta.
Neutral
Business Wire
1 month ago
CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx, together with study collaborators from leading transplant centers, will present the latest advancements in clinical evidence supporting its transplant care solutions at the Inter.
Charts implemented using Lightweight Charts™